Literature DB >> 34002067

Immunobiology and pathogenesis of hepatitis B virus infection.

Matteo Iannacone1,2,3, Luca G Guidotti4,5.   

Abstract

Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to cause a persistent infection, ultimately leading to cirrhosis and hepatocellular carcinoma. Over the past four decades, the basic principles of HBV gene expression and replication as well as the viral and host determinants governing infection outcome have been largely uncovered. Whereas HBV appears to induce little or no innate immune activation, the adaptive immune response mediates both viral clearance as well as liver disease. Here, we review our current knowledge on the immunobiology and pathogenesis of HBV infection, focusing in particular on the role of CD8+ T cells and on several recent breakthroughs that challenge current dogmas. For example, we now trust that HBV integration into the host genome often serves as a relevant source of hepatitis B surface antigen (HBsAg) expression during chronic infection, possibly triggering dysfunctional T cell responses and favouring detrimental immunopathology. Further, the unique haemodynamics and anatomy of the liver - and the changes they frequently endure during disease progression to liver fibrosis and cirrhosis - profoundly influence T cell priming, differentiation and function. We also discuss why therapeutic approaches that limit the intrahepatic inflammatory processes triggered by HBV-specific T cells might be surprisingly beneficial for patients with chronic infection.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34002067     DOI: 10.1038/s41577-021-00549-4

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  142 in total

Review 1.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

Review 2.  HBV cure: why, how, when?

Authors:  Massimo Levrero; Barbara Testoni; Fabien Zoulim
Journal:  Curr Opin Virol       Date:  2016-07-19       Impact factor: 7.090

Review 3.  Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.

Authors:  Stephen Locarnini; Angelos Hatzakis; Ding-Shinn Chen; Anna Lok
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 4.  Host-virus interactions in hepatitis B virus infection.

Authors:  Luca G Guidotti; Masanori Isogawa; Francis V Chisari
Journal:  Curr Opin Immunol       Date:  2015-07-15       Impact factor: 7.486

Review 5.  Adaptive immunity in HBV infection.

Authors:  Antonio Bertoletti; Carlo Ferrari
Journal:  J Hepatol       Date:  2016-04       Impact factor: 25.083

Review 6.  Therapeutic strategies for hepatitis B virus infection: towards a cure.

Authors:  Gregory C Fanning; Fabien Zoulim; Jinlin Hou; Antonio Bertoletti
Journal:  Nat Rev Drug Discov       Date:  2019-08-27       Impact factor: 84.694

Review 7.  Hepatitis B virus infection.

Authors:  Man-Fung Yuen; Ding-Shinn Chen; Geoffrey M Dusheiko; Harry L A Janssen; Daryl T Y Lau; Stephen A Locarnini; Marion G Peters; Ching-Lung Lai
Journal:  Nat Rev Dis Primers       Date:  2018-06-07       Impact factor: 52.329

8.  A global scientific strategy to cure hepatitis B.

Authors:  Peter A Revill; Francis V Chisari; Joan M Block; Maura Dandri; Adam J Gehring; Haitao Guo; Jianming Hu; Anna Kramvis; Pietro Lampertico; Harry L A Janssen; Massimo Levrero; Wenhui Li; T Jake Liang; Seng-Gee Lim; Fengmin Lu; M Capucine Penicaud; John E Tavis; Robert Thimme; Fabien Zoulim
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-04-10

9.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

Authors:  B Rehermann; C Ferrari; C Pasquinelli; F V Chisari
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

10.  Purification and biophysical characterization of hepatitis B antigen.

Authors:  C Y Kim; J G Tilles
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

View more
  38 in total

1.  Characterization of the TCR β Chain Repertoire in Peripheral Blood from Hepatitis B Vaccine Responders and Non-Responders.

Authors:  Jiezuan Yang; Yongtao Li; Jing Ye; Ju Wang; Haifeng Lu; Xinsheng Yao
Journal:  J Inflamm Res       Date:  2022-02-14

Review 2.  Hepatitis B virus e antigen and viral persistence.

Authors:  Kuen-Nan Tsai; Jing-Hsiung James Ou
Journal:  Curr Opin Virol       Date:  2021-10-28       Impact factor: 7.090

Review 3.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

4.  Down-regulated cylindromatosis enhances NF-κB activation and aggravates inflammation in HBV-ACLF patients.

Authors:  Xueyun Zhang; Yao Zhang; Pu Zhou; Jingwen Ai; Xiaoqin Liu; Quanbao Zhang; Zhengxin Wang; Hongyan Wang; Wenhong Zhang; Jiming Zhang; Yuxian Huang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

5.  Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated Cirrhosis.

Authors:  Yue Zhang; Nanxi Xiao; Qi Liu; Yuan Nie; Xuan Zhu
Journal:  Dis Markers       Date:  2022-05-25       Impact factor: 3.464

6.  Potential role of HBV DNA-induced CD8high T cell apoptosis in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Zifeng Wang; Fen Wang; Haiyang Ma; Shujuan Lv
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

Review 7.  Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection.

Authors:  Ilaria Montali; Andrea Vecchi; Marzia Rossi; Camilla Tiezzi; Amalia Penna; Valentina Reverberi; Diletta Laccabue; Gabriele Missale; Carolina Boni; Paola Fisicaro
Journal:  Biomedicines       Date:  2022-05-24

8.  Developing a cure for chronic hepatitis B requires a fresh approach.

Authors:  Matteo Iannacone; Luca G Guidotti
Journal:  Nature       Date:  2022-03       Impact factor: 69.504

9.  Toll- like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: a case control study in Egyptian patients.

Authors:  Asmaa M Elbrolosy; Naglaa S Elabd; Gamalat A ElGedawy; Mai Abozeid; Mervat Abdelkreem; Belal Montaser; Emad M Eed; Moamena S Elhamouly
Journal:  Clin Exp Med       Date:  2022-02-04       Impact factor: 3.984

Review 10.  Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery.

Authors:  Dariusz Zakrzewicz; Joachim Geyer
Journal:  Biomedicines       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.